Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Medicine Quality Research Group organised a multidisciplinary hybrid meeting at Keble College, Oxford, July 3 to 6, for the FORESFA project ‘Forensic epidemiology and impact of substandard and falsified antimicrobials on public health’, funded by a Wellcome Collaborative Award.

FORESFA conference 2022 Oxford group photo

FORESFA

Fifty-three colleagues from 12 countries, including pharmacists, forensic geneticists and chemists, modelers, sociologists, data scientists, informaticians, microbiologists, criminologists, public engagement specialists and food safety scientists, with national and international organisation representatives, met for vibrant discussions and planning for the project.

Those present in person went for after lunch walks, including to the Sir William Dunn School of Pathology blue plaque commemorating where penicillin was first brewed up to administer to patients.

VIE

The Group continued with another, overlapping, multidisciplinary hybrid meeting at Keble, from July 6 to 8, to discuss the Vaccine Identity Evaluation (VIE) project, that is evaluating devices for screening for substandard and falsified (SF) vaccines in supply chains.

The VIE team, of the CTMGH, Department of Biochemistry and Department of Chemistry, Oxford and the Science and Technology Facilities Council’s Rutherford Appleton Laboratory (RAL), were joined by sixty colleagues from eleven countries including vaccine and device manufacturers, medicines regulators, virologists, chemists, physicists, forensic scientists, data scientists, police and investigators, sociologists and translational research experts.

Pilot data were discussed and much progress made on future collaborative plans with a vision to bring about a step change in our ability to detect SF vaccines. The diverse devices were demonstrated at RAL and in Biochemistry and Chemistry.

Visit the page 'Vaccine Identity Evaluation (VIE) in the Zitzmann lab' on the Biochemistry Department website.

Similar stories

Watch our webinar - Radical cure of vivax malaria: can we do better?

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Shobhana Nagraj, Women in Science

Clinical Researcher Shobhana Nagraj, from the Health Systems Collaboratives in Oxford, tells us about the female role models who inspired her to follow her dreams

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Expert Comment: Biotechnology allows us to make unprecedented interventions for conservation

In the wake of high-profile reports on the devastating toll human activity has had on global biodiversity, nations are expected to adopt the Convention on Biodiversity post-2020 framework that outlines measures to ensure humans live in harmony with nature.

Researchers call for antimicrobial resistance surveillance to be improved

The number of studies reporting antimicrobial resistance (AMR) data has increased in Africa, South and South East Asia according to new research in the International Journal of Infectious Diseases.

Meta-analysis informed the updated WHO guidelines for treatment of uncomplicated malaria in the first trimester of pregnancy

A new WWARN meta-analysis, commissioned by the World Health Organization and which informed a change to its treatment guidelines, has been published in The Lancet. The study provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.